GlucoTrack, Inc. (GCTK)
USD 0.23
(-5.78%)
USD 0.23
(-5.78%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 196 Thousand USD | 0.51% |
| 2022 | 195 Thousand USD | -22.0% |
| 2021 | 250 Thousand USD | -31.13% |
| 2020 | 363 Thousand USD | -3.87% |
| 2019 | 377.59 Thousand USD | 124.47% |
| 2018 | 168.22 Thousand USD | -7.96% |
| 2017 | 182.76 Thousand USD | 12.8% |
| 2016 | 162.03 Thousand USD | 1.07% |
| 2015 | 160.31 Thousand USD | -74.06% |
| 2014 | 617.99 Thousand USD | -10.84% |
| 2013 | 693.09 Thousand USD | 1751.85% |
| 2012 | 37.42 Thousand USD | -93.83% |
| 2011 | 606.14 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 274 Thousand USD | 0.74% |
| 2024 Q1 | 272 Thousand USD | 38.78% |
| 2023 Q4 | 196 Thousand USD | 6.52% |
| 2023 Q2 | 189 Thousand USD | -2.07% |
| 2023 FY | 196 Thousand USD | 0.51% |
| 2023 Q3 | 184 Thousand USD | -2.65% |
| 2023 Q1 | 193 Thousand USD | -1.03% |
| 2022 Q2 | 192 Thousand USD | -14.29% |
| 2022 Q3 | 191 Thousand USD | -0.52% |
| 2022 Q4 | 195 Thousand USD | 2.09% |
| 2022 FY | 195 Thousand USD | -22.0% |
| 2022 Q1 | 224 Thousand USD | -10.4% |
| 2021 Q3 | 266 Thousand USD | -10.44% |
| 2021 Q4 | 250 Thousand USD | -6.02% |
| 2021 Q1 | 341 Thousand USD | -6.06% |
| 2021 FY | 250 Thousand USD | -31.13% |
| 2021 Q2 | 297 Thousand USD | -12.9% |
| 2020 Q4 | 363 Thousand USD | 5.49% |
| 2020 Q1 | 334.44 Thousand USD | -11.43% |
| 2020 FY | 363 Thousand USD | -3.87% |
| 2020 Q2 | 303.32 Thousand USD | -9.3% |
| 2020 Q3 | 344.09 Thousand USD | 13.44% |
| 2019 FY | 377.59 Thousand USD | 124.47% |
| 2019 Q1 | 372.44 Thousand USD | 121.4% |
| 2019 Q3 | 333.97 Thousand USD | -5.57% |
| 2019 Q4 | 377.59 Thousand USD | 13.06% |
| 2019 Q2 | 353.66 Thousand USD | -5.04% |
| 2018 FY | 168.22 Thousand USD | -7.96% |
| 2018 Q4 | 168.22 Thousand USD | -3.03% |
| 2018 Q3 | 173.48 Thousand USD | 1.04% |
| 2018 Q2 | 171.69 Thousand USD | -4.3% |
| 2018 Q1 | 179.42 Thousand USD | -1.83% |
| 2017 Q1 | 170.15 Thousand USD | 5.01% |
| 2017 Q2 | 178.18 Thousand USD | 4.72% |
| 2017 FY | 182.76 Thousand USD | 12.8% |
| 2017 Q3 | 176.87 Thousand USD | -0.74% |
| 2017 Q4 | 182.76 Thousand USD | 3.33% |
| 2016 Q3 | 166.45 Thousand USD | 2.76% |
| 2016 FY | 162.03 Thousand USD | 1.07% |
| 2016 Q4 | 162.03 Thousand USD | -2.66% |
| 2016 Q2 | 161.99 Thousand USD | 474.73% |
| 2016 Q1 | 28.18 Thousand USD | -82.42% |
| 2015 Q4 | 160.31 Thousand USD | -0.17% |
| 2015 FY | 160.31 Thousand USD | -74.06% |
| 2015 Q3 | 160.58 Thousand USD | -3.64% |
| 2015 Q2 | 166.64 Thousand USD | 6.78% |
| 2015 Q1 | 156.06 Thousand USD | -74.75% |
| 2014 Q4 | 617.99 Thousand USD | -5.17% |
| 2014 Q1 | 23.83 Thousand USD | -96.56% |
| 2014 Q2 | 698.37 Thousand USD | 2829.67% |
| 2014 FY | 617.99 Thousand USD | -10.84% |
| 2014 Q3 | 651.71 Thousand USD | -6.68% |
| 2013 Q3 | 680.82 Thousand USD | 2.79% |
| 2013 Q2 | 662.32 Thousand USD | 3.16% |
| 2013 Q4 | 693.09 Thousand USD | 1.8% |
| 2013 Q1 | 642.04 Thousand USD | 1615.45% |
| 2013 FY | 693.09 Thousand USD | 1751.85% |
| 2012 Q3 | 604.56 Thousand USD | 1.43% |
| 2012 Q1 | 625.83 Thousand USD | 3.25% |
| 2012 Q2 | 596.06 Thousand USD | -4.76% |
| 2012 FY | 37.42 Thousand USD | -93.83% |
| 2012 Q4 | 37.42 Thousand USD | -93.81% |
| 2011 Q4 | 606.14 Thousand USD | -3.16% |
| 2011 FY | 606.14 Thousand USD | 0.0% |
| 2011 Q3 | 625.9 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 85.7 Million USD | 99.771% |
| AngioDynamics, Inc. | 5.91 Million USD | 96.686% |
| AtriCure, Inc. | 74.49 Million USD | 99.737% |
| Avinger, Inc. | 15.39 Million USD | 98.727% |
| Azenta, Inc. | 60.43 Million USD | 99.676% |
| BioLife Solutions, Inc. | 42.69 Million USD | 99.541% |
| The Cooper Companies, Inc. | 2.56 Billion USD | 99.992% |
| Daxor Corporation | 755.65 Thousand USD | 74.062% |
| Ekso Bionics Holdings, Inc. | 7.16 Million USD | 97.266% |
| Femasys Inc. | 6.7 Million USD | 97.075% |
| Harvard Bioscience, Inc. | 42.77 Million USD | 99.542% |
| Hologic, Inc. | 2.53 Billion USD | 99.992% |
| ICU Medical, Inc. | 1.7 Billion USD | 99.989% |
| Intuitive Surgical, Inc. | 89.8 Million USD | 99.782% |
| KORU Medical Systems, Inc. | 4.44 Million USD | 95.591% |
| LeMaitre Vascular, Inc. | 19.09 Million USD | 98.974% |
| Innovative Eyewear, Inc. | - USD | -Infinity% |
| Innovative Eyewear, Inc. | - USD | -Infinity% |
| Masimo Corporation | 970 Million USD | 99.98% |
| Microbot Medical Inc. | 231 Thousand USD | 15.152% |
| Meihua International Medical Technologies Co., Ltd. | 7.33 Million USD | 97.326% |
| Merit Medical Systems, Inc. | 891.35 Million USD | 99.978% |
| Nephros, Inc. | 1.83 Million USD | 89.325% |
| NovoCure Limited | 596.24 Million USD | 99.967% |
| NEXGEL, Inc. | 2.79 Million USD | 92.995% |
| NEXGEL, Inc. | 2.79 Million USD | 92.995% |
| Singular Genomics Systems, Inc. | 75.28 Million USD | 99.74% |
| OraSure Technologies, Inc. | 13.5 Million USD | 98.549% |
| Pro-Dex, Inc. | 13.54 Million USD | 98.553% |
| Pulse Biosciences, Inc. | 9.14 Million USD | 97.857% |
| Predictive Oncology Inc. | 2.85 Million USD | 93.139% |
| Precision Optics Corporation, Inc. | 3.43 Million USD | 94.293% |
| QuidelOrtho Corporation | 2.61 Billion USD | 99.993% |
| Repligen Corporation | 711.8 Million USD | 99.972% |
| Sanara MedTech Inc. | 11.79 Million USD | 98.338% |
| STAAR Surgical Company | 35.83 Million USD | 99.453% |
| Sharps Technology, Inc. | - USD | -Infinity% |
| Utah Medical Products, Inc. | 342 Thousand USD | 42.69% |
| DENTSPLY SIRONA Inc. | 2.29 Billion USD | 99.991% |
| Jin Medical International Ltd. | 4.11 Million USD | 95.235% |